The Bill & Melinda Gates Foundation has awarded a $5M grant to Inovio Pharmaceuticals (NASDAQ:INO)
to accelerate the testing and scale-up of the Cellectra 3PSP smart
device for the intradermal delivery of INO-4800, its potential DNA
vaccine for COVID-19.
The company plans to launch a Phase 1 study next
month enabled by up to $9M in funding from the Coalition for Epidemic
Preparedness Innovations (CEPI).
Cellectra 3PSP is a small, portable, hand-held, battery-operated device that is designed to administer vaccines and therapies.
Inovio says its goal is to deliver 1M doses of INO-4800 and the requisite number of Cellectra devices by year-end.
https://seekingalpha.com/news/3551022-inovio-up-19-premarket-on-gates-grant-to-support-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.